RBC raises target for BeOne Medicines stock to USD 459.00

Published on 10/08/2026 at 21:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 1.71 billion in the second quarter, up 30.00 percent. BeOne Medicines stock costs EUR 311.00 after EUR 325.00 on October 8, 2026.

Key points in brief

RBC Capital raised its BeOne Medicines price target from USD 450.00 to USD 459.00 on October 8, 2026 while maintaining Outperform.
Second-quarter revenue reached USD 1.71 billion, up 30.00 percent year over year, according to the August 5 earnings call.
BeOne Medicines stock was at EUR 311.00 at Lang & Schwarz on October 8, 2026, down 4.31 percent from the EUR 325.00 prior close.
The next expected earnings date is November 5, 2026.

ONC, US07725L1026, Illustration mit AI erstellt.

BeOne Medicines stock (ISIN US07725L1026) is at the center of a fresh analyst revision after RBC Capital raised its price target from USD 450.00 to USD 459.00 on October 8, 2026 while maintaining an Outperform rating. The move comes as the oncology company enters the final months of a year marked by 30.00 percent second-quarter revenue growth.

RBC lifts target to USD 459

According to GuruFocus on October 8, 2026, RBC Capital analyst Leonid Timashev kept the Outperform rating and increased the target by USD 9.00, equivalent to a 2.00 percent rise from the previous target. GuruFocus also reported USD 321,128,066 in insider sales over the preceding three months, a counter-factor to the bullish target revision.

Three dated milestones

Yahoo Finance reported the August 5, 2026 second-quarter call, where revenue reached USD 1.70 billion and GAAP earnings per ADS reached USD 2.05. On September 14, 2026, Quartr summarized five pivotal solid-tumor programs and a 70.00 percent response rate for the BGB-43395 program. The October 8, 2026 RBC revision is the latest of the three milestones, lifting the target to USD 459.00.

What does revenue growth mean?

The second-quarter result gives the valuation discussion an operating anchor. Yahoo Finance reported BRUKINSA global revenue above USD 1.20 billion, up 31.00 percent year over year, while TEVIMBRA generated USD 229.00 million, up 18.00 percent versus the prior period. Management also raised its 2026 revenue outlook by USD 300.00 million to USD 6.60 billion to USD 6.80 billion.

Next earnings date and price

StockHub lists November 5, 2026 as the expected next earnings date. The primary Nasdaq quote was USD 347.45 at 3:10 p.m. EDT on October 8, 2026, against a 52-week range of USD 253.95 to USD 385.22 and a market capitalization of USD 37.1 billion.

After-hours, BeOne Medicines was trading at EUR 311.00 at Lang & Schwarz on October 8, 2026, minus 4.31 percent versus the prior close of EUR 325.00 on October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of BeOne Medicines stock.